Risa Yamazaki

Risa Yamazaki

Auto-generated profile, based on publicly available information

Risa Yamazaki

Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
RYRisa Yamazaki
Risa Yamazaki
Yoshitoshi KasuyaYoshitoshi Kasuya
Yoshitoshi Kasuya
TFTetsuo Fujita
Tetsuo Fujita
HUHiroki Umezawa
Hiroki Umezawa
MYMadoka Yanagihara
Madoka Yanagihara
TMToshihiko Murayama
Toshihiko Murayama
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder that is characterized by aberrant tissue remodeling and the formation of fibroblastic foci that are composed of fibrogenic myofibroblasts. TGF‐β1 is one of the factors that are responsible for fibrosis as it promotes fibroblast to myofibroblast differentiation (FMD) and is associated with up‐regulation of α‐smooth muscle actin. Therefore, inhibition of FMD may represent an effective strategy for the treatment of IPF. Here, we describe the treatment of human lung fibroblasts (WI‐38 and HFL‐1 cells) with cyclosporine A (CsA), which reduces TGF‐β1–induced FMD via degradation of hypoxia‐inducible factor‐1α (HIF‐1α). In addition, in primary myofibroblast‐like cells that were obtained from a patient with pulmonary fibrosis, treatment with CsA and an HIF‐1α inhibitor (HIFi) decreased the expression levels of α‐smooth muscle actin and fibronectin, which indicated that CsA and HIFi promote dedifferentiation of myofibroblasts. In mice intratracheally administered CsA or HIFi at an early fibrotic stage [7, 8, and 9 d postinstillation (dpi) of bleomycin], marked alleviation of lung fibrosis was observed at 14 dpi. These results suggest that CsA exhibits antifibrotic effects by degrading HIF‐1α and that the CsA–HIF‐1α axis provides new insights into therapeutic options for the treatment of IPF.—Yamazaki, R., Kasuya, Y., Fujita, T., Umezawa, H., Yanagihara, M., Nakamura, H., Yoshino, I., Tatsumi, K., Murayama, T. Antifibrotic effects of cyclosporine A on TGF‐β1–treated lung fibroblasts and lungs from bleomycin‐treated mice: role of hypoxia‐inducible factor‐1α. FASEB J . 31, 3359–3371 (2017). www.fasebj.org

1 August 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HNHiroyuki Nakamura
Hiroyuki Nakamura
YMYuta Moriyama
Yuta Moriyama
TMTomohiko Makiyama
Tomohiko Makiyama
SEShunsuke Emori
Shunsuke Emori
HYHisahiro Yamashita
Hisahiro Yamashita
TMToshihiko Murayama
Toshihiko Murayama
Lactosylceramide (LacCer) is a member of the glycosphingolipid family and is known to be a bioactive lipid in various cell physiological processes. However, the direct targets of LacCer and cellular events mediated by LacCer are largely unknown. In this study, we examined the effect of LacCer on the release of arachidonic acid (AA) and the activity of cytosolic phospholipase A2α (cPLA2α). In CHO-W11A cells, treatment with 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP), an inhibitor of glucosylceramide synthase, reduced the glycosphingolipid level, and the release of AA induced by A23187 or platelet-activating factor was inhibited. The addition of LacCer reversed the PPMP effect on the stimulus-induced AA release. Exogenous LacCer stimulated the release of AA, which was decreased by treatment with an inhibitor of cPLA2α or silencing of the enzyme. Treatment of CHO-W11A cells with LacCer induced the translocation of full-length cPLA2α and its C2 domain from the cytosol to the Golgi apparatus. LacCer also induced the translocation of the D43N mutant of cPLA2α. Treatment of L929 cells with TNF-α induced LacCer generation and mediated the translocation of cPLA2α and AA release, which was attenuated by treatment with PPMP. In vitro studies were then conducted to test whether LacCer interacts directly with cPLA2α. Phosphatidylcholine vesicles containing LacCer increased cPLA2α activity. LacCer bound to cPLA2α and its C2 domain in a Ca2+-independent manner. Thus, we propose that LacCer is a direct activator of cPLA2α.

26 April 2017 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
HNHiroyuki Nakamura
Hiroyuki Nakamura
YMYuta Moriyama
Yuta Moriyama
KWKazuaki Watanabe
Kazuaki Watanabe
STSatoshi Tomizawa
Satoshi Tomizawa
RYRisa Yamazaki
Risa Yamazaki
TMToshihiko Murayama
Toshihiko Murayama

1 December 2012 in European Journal of Pharmacology
Verified
Journal Article
Closed access
TKTatsuo Kawashima
Tatsuo Kawashima
RYRisa Yamazaki
Risa Yamazaki
YMYasuo Matsuzawa
Yasuo Matsuzawa
EYErika Yamaura
Erika Yamaura
MTMamoru Takabatake
Mamoru Takabatake
TMToshihiko Murayama
Toshihiko Murayama

10 July 2021 in SLEEP
Verified
Journal Article
Closed access
PDF file
RYRisa Yamazaki
Risa Yamazaki
DWDianru Wang
Dianru Wang
ALAnna De Laet
Anna De Laet
RMRenato Maciel
Renato Maciel
CAClaudio Agnorelli
Claudio Agnorelli
PLPierre-Hervé Luppi
Pierre-Hervé Luppi
Study Objectives: Determine whether in the hippocampus and the supramammillary nucleus (SuM) the same neurons are reactivated when mice are exposed 1 week apart to two periods of wakefulness (W-W), paradoxical sleep rebound (PSR-PSR) or a period of W followed by a period of PSR (W-PSR) Methods: We combined the innovative TRAP2 mice method in which neurons expressing cFos permanently express tdTomato after tamoxifen injection with cFos immunohistochemistry. Results: We found out that a large number of tdTomato+ and cFos+ cells are localized in the dentate gyrus (DG) after PSR and W while CA1 and CA3 contained both types of neurons only after W. The number of cFos+ cells in the infrapyramidal but not the suprapyramidal blade of the DG was positively correlated with the amount of PS. In addition, we did not find double-labeled cells in the DG whatever the group of mice. In contrast, a high percentage of CA1 neurons were double-labeled in W-W mice. Finally, in the supramammillary nucleus, a large number of cells were double-labeled in W-W, PSR-PSR but not in W-PSR mice. Conclusions: Altogether, our results are the first to show that different neurons are activated during W and PS in the supramammillary nucleus and the hippocampus. Further, we showed for the first time that granule cells of the infrapyramidal blade of the DG are activated during PS but not during W. Further experiments are now needed to determine whether these granule cells belong to memory engrams inducing memory reactivation during PS.

14 February 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
HNHiroyuki Nakamura
Hiroyuki Nakamura
YZYuan Zhou
Yuan Zhou
YSYuka Sakamoto
Yuka Sakamoto
AYAyako Yamazaki
Ayako Yamazaki
EKEon Kurumiya
Eon Kurumiya
TMToshihiko Murayama
Toshihiko Murayama
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease. The disease involves excessive accumulation of fibroblasts and myofibroblasts, and myofibroblasts differentiated by pro-fibrotic factors promote the deposition of extracellular matrix proteins such as collagen and fibronectin. Transforming growth factor-β1 is a pro-fibrotic factor that promotes fibroblast-to-myofibroblast differentiation (FMD). Therefore, inhibition of FMD may be an effective strategy for IPF treatment. In this study, we screened the anti-FMD effects of various iminosugars and showed that some compounds, including N-butyldeoxynojirimycin (NB-DNJ, miglustat, an inhibitor of glucosylceramide synthase (GCS)), a clinically approved drug for treating Niemann-Pick disease type C and Gaucher disease type 1, inhibited TGF-β1-induced FMD by inhibiting the nuclear translocation of Smad2/3. N-butyldeoxygalactonojirimycin having GCS inhibitory effect did not attenuate the TGF-β1-induced FMD, suggesting that NB-DNJ exerts the anti-FMD effects by GCS inhibitory effect independent manner. N-butyldeoxynojirimycin did not inhibit TGF-β1-induced Smad2/3 phosphorylation. In a mouse model of bleomycin (BLM)-induced pulmonary fibrosis, intratracheal or oral administration of NB-DNJ at an early fibrotic stage markedly ameliorated lung injury and deterioration of respiratory functions, such as specific airway resistance, tidal volume, and peak expiratory flow. Furthermore, the anti-fibrotic effects of NB-DNJ in the BLM-induced lung injury model were similar to those of pirfenidone and nintedanib, which are clinically approved drugs for the treatment of IPF. These results suggest that NB-DNJ may be effective for IPF treatment.